I don’t agree with what you're trying to imply. The trial is...

I don’t agree with what you're trying to imply.

The trial is being conducted at MD Anderson Cancer Center, one of the most respected cancer research institutions in the world. It’s highly unlikely they would put their clinical and scientific reputation on the line to support a news release that had no credible basis, especially for the sake of a biotech company raising capital.

The results reported — including 2 out of 3 patients achieving CRi — are early but clinically meaningful, especially for newly diagnosed AML patients who are ineligible for chemo or transplant. The trial’s explicit aim is to evaluate the synergy between standard care and CORE-NK cells, and the outcomes, while preliminary, suggest the NK cell therapy may more than likely be contributing to patient responses.

Of course, more data is needed before drawing firm conclusions, but dismissing the update as purely a cash grab overlooks the credibility of the institution, the credibility of our good Dr Bec, & of the professor leading the study.